Extract
The novel coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1, 2]. The World Health Organization (WHO) declared the COVID-19 outbreak a pandemic on 11 March, 2020, demanding effective national and global mitigation measures, strong public health response and coordination. To date, the SARS-CoV-2 pandemic has affected over 5 million individuals worldwide with an overall 7.02% (median 3.41%, ranges 0.06% to 31.25%) case fatality ratio (European Center for Disease Prevention and Control dashboard: www.ecdc.europa.eu, as of 22 May, 2020) [3]. This ratio may be overstated since it is based primarily on hospitalised or notified cases.
Abstract
This paper offers practical and feasible actions to be implemented at patient, healthcare provider and community level to combat COVID-19 while attending, maintaining and strengthening ongoing health management in people with lung diseases https://bit.ly/30yNyhP
Acknowledgement
All authors are active leaders of organisations comprising the network of the Global Alliance against chronic Respiratory Diseases (GARD), but the content and opinions expressed in this paper are those of the authors and they do not purport to reflect the opinions, views, positions or standing policies of any organisations, agencies or institutions which the authors are affiliated with.
Footnotes
Conflict of interest: T. To has nothing to disclose.
Conflict of interest: G. Viegi has nothing to disclose.
Conflict of interest: A. Cruz has nothing to disclose.
Conflict of interest: L. Taborda-Barata reports honoraria from AstraZeneca, Novartis, Menarini and Vitoria Laboratories as payment for giving scientific lectures in the context of training sessions in the respiratory field or allergy, for healthcare professionals.
Conflict of interest: M. Asher has nothing to disclose.
Conflict of interest: D. Behera has nothing to disclose.
Conflict of interest: K. Bennoor has nothing to disclose.
Conflict of interest: L-P. Boulet has nothing to disclose.
Conflict of interest: J. Bousquet reports personal fees for advisory board work, consultancy and lectures from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi-Aventis, Takeda, Teva and Uriach, and owns shares in KYomed-Innov, outside the submitted work.
Conflict of interest: P. Camargos has nothing to disclose.
Conflict of interest: C. Conceiçao has nothing to disclose.
Conflict of interest: S. Gonzalez Diaz has nothing to disclose.
Conflict of interest: A. El-Sony has nothing to disclose.
Conflict of interest: M. Erhola has nothing to disclose.
Conflict of interest: M. Gaga reports grants and personal fees from Novartis and Menarini, grants from Galapagos and Elpen, personal fees from BMS, MSD and AZ, outside the submitted work.
Conflict of interest: D. Halpin reports personal fees from AstraZeneca, Chiesi, GlaxoSmithKline, Novartis, Pfizer and Sanofi, personal fees and non-financial support from Boehringer Ingelheim and Novartis, outside the submitted work.
Conflict of interest: L. Harding has nothing to disclose.
Conflict of interest: T. Maglakelidze has nothing to disclose.
Conflict of interest: M.R. Masjedi has nothing to disclose.
Conflict of interest: Y. Mohammad has nothing to disclose.
Conflict of interest: E. Nunes has nothing to disclose.
Conflict of interest: B. Pigearias has nothing to disclose.
Conflict of interest: T. Sooronbaev has nothing to disclose.
Conflict of interest: R. Stelmach reports grants from São Paulo Research Foundation and MSD, grants and personal fees from Novartis, grants, personal fees and non-financial support from AstraZeneca and Chiesi, personal fees and non-financial support from Boehringer Ingelheim, outside the submitted work.
Conflict of interest: I. Tsiligianni reports grants from Elpen and GSK Hellas, personal fees from Novartis, Boehringer Ingelheim, GSK and Menarini, outside the submitted work.
Conflict of interest: L.T. Tuyet Lan has nothing to disclose.
Conflict of interest: A. Valiulis has nothing to disclose.
Conflict of interest: C. Wang has nothing to disclose.
Conflict of interest: S. Williams has nothing to disclose.
Conflict of interest: A. Yorgancioglu has nothing to disclose.
- Received May 10, 2020.
- Accepted June 5, 2020.
- Copyright ©ERS 2020
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.